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Background: Postpartum hemorrhage (PPH) is the leading cause of maternal death in low-
income countries and is the primary cause of approximately one-quarter of global maternal 
deaths. The purpose of this paper is to provide a review of PPH prevention interventions, with 
a particular focus on misoprostol, and the challenges and opportunities that preventing PPH in 
low-resource settings presents.
Methods: Using PubMed, we conducted a review of the literature on the randomized controlled 
trials of interventions to prevent PPH. We then searched PubMed and Google Scholar for non-
randomized field trials of interventions to prevent PPH. We limited our review to interventions 
that are discussed in the current World Health Organization (WHO) recommendations for PPH 
prevention and present evidence regarding the use of these interventions. We focused our review 
on nondrug PPH prevention interventions compared with no intervention and uterotonics versus 
placebo; this review does not decipher the relative effectiveness of uterotonic drugs. We describe 
challenges to and opportunities for scaling up PPH prevention interventions.
Results: Active management of the third stage of labor is considered the “gold standard” strategy 
for reducing the incidence of PPH. It combines nondrug interventions (controlled cord trac-
tion and cord clamping) with the administration of an uterotonic drug, the preferred uterotonic 
being oxytocin. Unfortunately, oxytocin has limited application in resource-poor countries, due 
to its heat instability and required administration by a skilled provider. New heat-stable drugs 
and drug formulations are currently in development that may improve the prevention of PPH; 
however, misoprostol is a viable option for provision at home by a lay health care worker or the 
woman herself, in the interim.
Conclusion: As the main cause of maternal mortality worldwide, PPH prevention interventions 
need to be prioritized. Increased access to prophylactic uterotonics, regardless of where deliveries 
occur, should be the primary means of reducing the burden of this complication.
Keywords: PPH prevention, uterotonics, AMTSL, misoprostol, oxytocin
Introduction
Every year more than 14 million cases of obstetric hemorrhage occur, resulting in an 
estimated 127,000 deaths.1 Postpartum hemorrhage (PPH), blood loss of 500 mL or 
more, accounts for the majority of these hemorrhage deaths.2 PPH is the leading cause 
of maternal death in low income countries and is the primary cause of approximately 
one-quarter of global maternal deaths.3 Among PPH survivors, an estimated 12% will 
suffer from the consequences of severe anemia.2
Several factors contribute to the high PPH mortality estimates. In most developing 
countries, 50% or more of deliveries are attended by unskilled providers at home.4 In 
addition, health facilities are often not adequately staffed or lack medicines that can 
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address PPH.5 These structural barriers are further compli-
cated by difficulties in predicting who will develop PPH. 
Many women who develop PPH do not present with any of 
the risk factors typically associated with the complication.6 
Consequently, PPH is an obstetric complication that requires 
effective preventive interventions, tailored to the diverse 
needs of women and providers in resource-poor settings.
The purpose of this paper is to present current perspec-
tives on the prevention of PPH, particularly in resource 
poor-settings, where PPH is the leading cause of maternal 
mortality.3 We reviewed historical events and the current evi-
dence related to PPH prevention and highlight the progress in 
policy and program implementation to reduce this disease. We 
reviewed the current strategies being implemented to prevent 
PPH, ranging from active management of the third stage of 
labor (AMTSL) in health facilities to the use of misoprostol in 
home births, which was given particular attention. In addition, 
we looked at challenges to the implementation and scale-up 
of these interventions, as well as examples of ongoing efforts 
that could be positions as opportunities to increase access to 
PPH prevention interventions.
Material and methods
Using PubMed, we conducted a review of the literature on 
randomized controlled trials (RCTs) of interventions to pre-
vent PPH. We then searched PubMed and Google Scholar for 
nonrandomized field trials of interventions to prevent PPH. 
We limited our review to interventions that are discussed 
in the current World Health Organization (WHO) recom-
mendations for PPH prevention, which we consider to be 
key interventions, and present evidence on the use of these 
interventions from 2000 to 2013. The following search terms 
were used, among others, in varying combinations: “postpar-
tum hemorrhage,” “PPH,” “PPH prevention interventions,” 
“active management of the third stage of labor,” “AMTSL,” 
“controlled cord traction,” “cord clamping,” “uterine mas-
sage,” “oxytocin,” “ergometrine,” “misoprostol,” “systematic 
review,” “Cochrane review,” “randomized controlled trial,” 
“RCT,” “operations research,” “low-resource settings,” and 
“developing countries.” We assessed the evidence from RCTs 
of PPH prevention interventions, as well as evidence from 
field trials and implementation programs. We focused our 
review on comparisons of nondrug PPH prevention inter-
ventions versus no intervention and of uterotonics versus 
placebo; this review was not intended to decipher the rela-
tive  effectiveness of uterotonic drugs. The interventions and 
conventional uterotonic drugs reviewed are those presumed 
to, either alone or in combination with other drugs, prevent 
PPH. The nondrug interventions included were AMTSL and 
the specific components (ie, controlled cord traction, cord 
clamping, and uterine massage). The conventional uterotonics 
included were oxytocin, ergot-based alkaloid (ergometrine), 
and misoprostol. To avoid duplication, we started with sys-
tematic reviews (often Cochrane Reviews) conducted since 
2000 and then added individual studies conducted after the 
review. We also searched for other studies not included in 
the most recent reviews that would meet our search criteria, 
including  peer-reviewed articles, documents in the gray 
literature, manuals, reports, clinical guidelines, and relevant 
publications from organizations working to promote PPH 
prevention, such as the WHO, the International Federation 
of Gynecology and Obstetrics (FIGO), the International 
Confederation of Midwives (ICM), as well as the work of 
many other nongovernmental organizations.
We recognize the barriers to implementation that develop-
ing countries may face and have described the challenges to 
and opportunities for scaling up recommended interventions. 
We focused specifically on scalability in light of limited 
access to services and shortages in skilled health care work-
ers and commodities.
Important events in the history  
of PPH prevention
Figure 1 presents a timeline of the important milestones 
related to PPH prevention, including discoveries, research 
publications, policies, and programs. To provide a historical 
perspective, we started in 1953 with the elucidation of the 
amino acid sequence of oxytocin, followed by its biochemi-
cal synthesis.7−10 Following these discoveries, a landmark 
in the history of PPH prevention occurred when the three 
components of AMTSL were first described in 1962: the 
administration of a prophylactic uterotonic drug, early 
cord cutting and clamping, and controlled cord traction.11 
However, it was not until the 1980s that data from an RCT 
of AMTSL revealed a significant reduction in the incidence 
of PPH compared with expectant management of the third 
stage of labor.12
More than two decades later, FIGO and ICM released 
their first statement on AMTSL.13 Then, recognizing that 
AMTSL could only be provided by skilled attendants, thus 
excluding women who deliver at home and limiting the cover-
age of this intervention, researchers were encouraged with the 
discovery and potential of a prostaglandin analogue in tablet 
form (ie, misoprostol).14 In 2005, the first placebo-controlled 
trial of misoprostol use for PPH prevention at home births was 
carried out, with promising results.15 The findings paved the 
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way for women with limited or no access to health facilities 
to have a PPH prevention intervention delivered at home, but 
the use of misoprostol for this purpose also introduced policy 
and program-related challenges. A considerable impediment 
was that at the time, misoprostol was an off-patent drug that 
was only on the market for the treatment of gastric ulcers, 
and in many developing countries, a product needs to be reg-
istered for the specific indication for which it is marketed. In 
2006, the WHO organized a technical consultation meeting 
to review the evidence for interventions to prevent and treat 
PPH; the following year, the WHO published recommenda-
tions based on this meeting, which included support of the use 
of misoprostol for PPH prevention in the absence of oxytocin 
but not at home births.16 By that time, individual country 
efforts to take advantage of misoprostol for PPH prevention 
had already started. In 2006, Nigeria was the first country in 
the world to register the use of misoprostol for PPH preven-
tion.17 Five years later, another important landmark policy 
reform occurred, which was the inclusion of misoprostol in 
the WHO Model List of Essential Medicines in 2011,18 fol-
lowed by a revision of the recommendations for the preven-
tion and treatment of PPH, in 2012.3 Around this time, the 
evidence regarding the impact of misoprostol in reducing 
PPH became clear, and its inclusion in the United Nations 
Commission on Life-Saving Commodities for Women and 
Children in 2012 was a testament to its contribution.19 The 
nonprofit organizations and professional associations with 
maternal health programs that attend largely to rural popula-
tions have recently issued a call for the scaling up of PPH 
prevention programs that include the use of misoprostol.20,21 
In addition, programs to strengthen labor and delivery prac-
tices continue to take place.22
Current evidence on interventions 
to prevent PPH
WHO recommendations
Table 1 presents a description of the key PPH prevention 
interventions and the WHO recommendations with respect 
to each. AMTSL is considered the “gold standard” strategy 
to reduce the incidence of PPH. It combines nondrug inter-
ventions with the administration of an uterotonic drug. The 
AMTSL preferred uterotonic is oxytocin,3 and the relative 
importance of other components has changed over time. 
Even though the WHO strongly recommends AMTSL, it 
also provides recommendations on the relative importance 
of each component. For example, the practice of controlled 
cord traction has a weak recommendation level, only to be 
practiced if small reductions in blood loss or durations of the 
third stage of labor are perceived to be beneficial (Table 1).3 
Cord clamping is now subdivided into late and early cord 
clamping; the latter is no longer recommended. Similarly, 
sustained uterine massage is no longer recommended in 
women who receive prophylactic oxytocin, although it was 
initially a common component of AMTSL. Instead, it is rec-
ommended that abdominal tonus assessment be conducted 
by a skilled provider, for all women (Table 1). However, the 
FIGO guidelines (2012) for the prevention of PPH in low-
resource settings defines AMTSL as: administration of 
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Figure 1 Important events in the prevention of PPH.
Abbreviations: AMTSL, active management of the third stage of labor; FIGO, International Federation of Gynecology and Obstetrics; ICM, International Confederation of 
Midwives; PPH, postpartum hemorrhage; RCT, randomized, control trials; UN, United Nations; WHO, World Health Organization.
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Table 1 Key interventions to prevent postpartum hemorrhage
Intervention WHO recommendations
Active management  
of the third stage  
of labor
Involves a combination of interventions, including: cord clamping and cutting; controlled cord traction; and use of an 
uterotonic agent
Specific recommendations for each component of the active management of the third stage of labor are provided below
Controlled cord  
traction
In settings where skilled birth attendants are available, controlled cord traction is recommended for vaginal births if the 
care provider and the parturient woman regard a small reduction in blood loss and a small reduction in the duration of 
the third stage of labor as important (weak recommendation, high-quality evidence)
In settings where skilled birth attendants are unavailable, controlled cord traction is not recommended 
(strong recommendation, moderate-quality evidence)
Only skilled provider can administer
Cord clamping Late cord clamping (in 1 to 3 minutes) is recommended for all births while initiating simultaneous essential newborn care 
(strong recommendation, moderate-quality evidence)
early cord clamping (less than 1 minute) is not recommended unless the neonate is asphyxiated and needs to be moved 
immediately for resuscitation (strong recommendation, moderate-quality evidence)
Only skilled provider can administer
Uterine massage Sustained uterine massage is not recommended as an intervention to prevent PPH in women who have received 
prophylactic oxytocin (weak recommendation, low-quality evidence)
Postpartum abdominal uterine tonus assessment for early identification of uterine atony is recommended for all women 
(strong recommendation, very low-quality evidence)
Only skilled provider can conduct routine uterine tone assessment. Women can self-administer continuous uterine 
massage in the absence of uterotonics
Oxytocin Oxytocin (10 IU, Iv/IM) is the recommended uterotonic drug for the prevention of PPH (strong recommendation, 
moderate-quality evidence)
Only skilled provider can administer
ergometrine In settings where oxytocin is unavailable, the use of other injectable uterotonics, like ergometrine/methylergometrine or fixed 
drug combinations of oxytocin and ergometrine) is recommended (strong recommendation, moderate-quality evidence)
Only skilled provider can administer
Misoprostol In settings where oxytocin is unavailable, oral misoprostol (600 μg) is one of the recommendations 
(strong recommendation, moderate-quality evidence)
Skilled and unskilled providers can administer; women can self-administer as well
Note: Data from WHO.3 
Abbreviations: IM, intramuscular; Iv, intravenous; PPH, postpartum hemorrhage; WHO, World Health Organization.
oxytocin, controlled cord traction, and uterine massage after 
the delivery of the placenta.23
Uterotonic drugs, such as oxytocin, ergometrine, and miso-
prostol, are strongly recommended (Table 1). Some researchers 
feel that oxytocin, which has minimal side effects and is safe 
to use among women with hypertension and preeclampsia, 
is all that is needed.24 Ergometrine, which has proven to be a 
powerful drug in reducing PPH, especially when combined 
with oxytocin, is known to be associated with serious side 
effects, such as severe vomiting and hypertension, and retained 
placenta when given intravenously.25 Misoprostol is similarly 
associated with side effects, but none have been shown to 
threaten the life of the mother or newborn.26 Its use is associ-
ated with significantly higher incidences of shivering and fever 
among mothers compared with placebo.26 Misoprostol has 
had recent success because of its heat stability and multiple 
routes of administration,27 which is critical in resource-poor 
countries.
It is important to note that all of these recommended inter-
ventions, with the exception of misoprostol  administration, 
are to be provided by skilled providers; as a result, most of 
them are available only to women who attend facility deliver-
ies. Large numbers of women living in countries with high 
maternal mortality deliver at home.4 Thus, the recent recom-
mendation supporting the inclusion of community health 
workers in the provision of misoprostol for the prevention of 
PPH was welcomed by the safe motherhood community.3,28
Randomized controlled trial data
The current recommendations with regards to PPH preven-
tion are based largely on RCT evidence. The clinical evidence 
of the initial AMTSL package from the 1980s showed that 
PPH could be reduced by 70% compared with expectant 
management.29 The most recent Cochrane review of active 
versus expectant management of the third stage of labor 
includes seven studies (Table 2), and the results indicate a 
significant reduction in the risk of PPH.29
Controlled cord traction was an initial component of 
AMTSL, but since 2000, three RCTs assessing AMTSL with 
and without cord traction were published, all of which found 
a nonsignificant difference in the risk of PPH (Table 2).30−32 
Regarding cord clamping, it was initially thought that early 
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Prevention of postpartum hemorrhage
cord clamping was best, but recent findings indicate that 
the timing is not critical.3 In 2013, the Cochrane Collabora-
tion researchers updated a previous review on the subject, 
and their findings confirmed that there are no significant 
differences in the risk of PPH between early and late cord 
clamping.33 Uterine massage, although not officially in the 
initial AMTSL package, was often included.3 However, a 
Cochrane review of two RCTs comparing uterine massage 
after birth and before or after the delivery of the placenta for 
the prevention of PPH found the differences between groups 
to be insignificant.34 In contrast, the efficacy of lower uterine 
segment compression versus nothing, in addition to oxytocin, 
cutting and clamping of the umbilical cord, and controlled 
cord traction, was found to be associated with a significantly 
lower incidence of PPH.35
Table 2 also presents the recent clinical evidence on the 
conventional uterotonics, demonstrating their importance in 
the prevention of PPH. A recent review of seven RCTs inves-
tigating the efficacy of oxytocin, three with intramuscular 
(IM) and four with intravenous (IV) preparations, showed that 
this uterotonic can significantly reduce the risk of PPH.36 In 
addition to the IM and IV preparations, two RCTs investigat-
ing the intraumbilical administration of oxytocin also found 
significant reductions in blood loss when compared with a 
control saline solution.37,38 Collectively, the results from these 
studies make it clear why oxytocin is the preferred uterotonic 
for PPH prevention.
In terms of the other uterotonics, a 2011 review of 
ergot alkaloids containing six studies (RCTs and quasi-
RCTs) found a significant reduction of PPH when these 
were administered in the third stage of labor.39 Regarding 
misoprostol, three recent reviews of RCTs comparing it to 
a placebo were identified, two published in 2012 and one 
in 2013.40−42 Results of these reviews showed both signifi-
cant reductions and nonsignificant reductions of PPH. The 
inconsistencies in the results could be due to the fact that 
misoprostol was assessed in different doses and routes and 
also that the individual studies’ inclusion criteria varied. The 
Cochrane review included 72 RCTs that assessed the effects 
of prophylactic prostaglandin use versus a placebo, eight 
of which assessed 600 μg oral or sublingual misoprostol 
(Table 2). Based on data from one trial, the authors of the 
review concluded that sublingual misoprostol was associated 
with significant reductions in the incidence of PPH. The data 
from seven trials on oral misoprostol were not totaled due 
to heterogeneity, but the authors concluded that compared 
with a placebo, oral misoprostol shows promising results.42 
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oral or sublingual misoprostol sound significant reduc-
tions in both acute and severe PPH.40 An even more recent 
meta-analysis of three RCTs showed that misoprostol does 
not provide significant reductions in the incidence of PPH 
when compared with placebo.41 Of the three RCTs included 
in these two latest reviews from 2012 and 2013, two of the 
RCTs were the same,15, 43 while one was different.44,45 Two 
seminal studies that were included showed a reduction in 
PPH of 24%45 and 47%15 in home births. Thus, factoring in 
the findings from the abovementioned reviews, all of which 
showed reductions in the risk of PPH, even if nonsignificant, 
it is understandable that the WHO ultimately supported the 
use of misoprostol in the absence of other uterotonics.
Nonrandomized data
Assessment of the nonrandomized data on the interventions 
to prevent PPH supports the clinical evidence from the RCTs. 
A quasi-experimental study of AMTSL in Vietnam (Table 3) 
showed similar levels of reduction in PPH to those found 
in the RCTs.46 An analysis of the independent or combined 
effect of uterotonic agents, controlled cord traction, and 
uterine massage from hospital-based data in four countries 
also showed similar results to the RCTs.47 No recent nonran-
domized or field trials were found reporting on the individual 
components of AMTSL, nor for oxytocin or ergometrine use 
in PPH prevention. On the contrary, evidence was found 
on the use of misoprostol to prevent PPH in facilities and 
home births.
All of the nonrandomized studies with blood loss and/or 
acute or severe PPH as outcomes showed that misoprostol 
use in the third stage of labor can significantly reduce PPH 
(Table 3). The evidence demonstrates that misoprostol can be 
effective in the prevention of PPH in home births.48-50 These 
findings are especially important for developing countries, 
which contribute the majority of PPH morbidity and mortal-
ity, where skilled attendance at delivery is limited, and where 
the use of the other two uterotonics is more challenging.51
Challenges in scaling up proven 
interventions
When considering scaling up PPH prevention interventions, 
it is important to consider where deliveries are occurring. 
Approximately 46% of all births worldwide take place out-
side of an institutional setting, attended by a traditional birth 
attendant, a relative, or no one.52,53 As previously mentioned, 
all WHO-recommended interventions other than misoprostol 
administration require a skilled birth attendant, and many 
require a facility-based delivery.3 One strategy for increasing 
access to these life-saving interventions is to encourage facil-
ity-based delivery, especially during prenatal care. However, 
one must keep in mind the limited number of skilled providers 
in settings where the most at-risk women deliver.4
In fact, it is in these high maternal mortality settings 
where the shortage of trained health providers is most acute. 
For example, 57 countries, many of which are among the 
least developed countries, have a shortage of approximately 
2.4 million physicians, nurses, and midwives. In sub-Saharan 
Africa specifically, their health care workforce shortage is so 
severe that they have only 1.3% of the world’s skilled provid-
ers, but 25% of the global burden of  disease.54 Most mortal-
ity from PPH would be eliminated if women had access to 
a skilled birth attendant, yet only 35% of births are attended 
by a skilled health worker in the least-developed countries.55 
It is estimated that the coverage of skilled attendance at birth 
is improving at a rate of less than 0.5% per year,56 thus it will 
be many years until we see adequate coverage at delivery; 
alternative solutions are needed.
For many developing countries, poor storage conditions 
and deficient public sector supply chains also contribute to 
the limited access to and utilization of uterotonic drugs. The 
storage of oxytocin and ergometrine can be particularly chal-
lenging, due to their instability in high temperatures and sen-
sitivity to light.51,57 Additionally, because these two drugs are 
only available in injection form, their administration is limited 
to skilled providers. Finally, in some settings where oxytocin 
and ergometrine are accessible, procurement of unregistered 
drugs may be prolific and the quality of the drugs may be 
compromised. For example, in Ghana, researchers found 
89% (N=90) of all ampoules of oxytocin and ergometrine 
tested did not meet the specifications for the active ingredi-
ent, which was not a result of being expired; this problem 
was present in both the public and private sector.58 On the 
other hand, misoprostol is reportedly more stable, available 
in tablet form, and can be provided through multiple routes 
of administration.59 However, all uterotonics can be exposed 
to health system failures, such as the case of oxytocin in 
Tanzania and Ethiopia, where the drugs were available but 
not properly distributed to health facilities.60,61
Even when available, uterotonics are not always used 
consistently to prevent PPH. A survey of 15 tertiary level 
facilities (including 452 vaginal deliveries) conducted by 
the Global Network for Perinatal and Reproductive Health 
showed that prophylactic oxytocin was used in 44% of the 
cases and was the least used of the three components of 
AMTSL assessed (use of early cord clamping was 79% and 
use of controlled cord traction was 70%).62 For home births 
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without a skilled provider, misoprostol has been distributed 
using a variety of approaches with or without a safe delivery 
kit, including distribution at antenatal care visits, at house-
hold visits by community health workers during pregnancy, 
at home births assisted by traditional birth attendants, and in 
some instances, through a combination of these methods.63 
None of these approaches are without challenges related to 
access and utilization of the drug. For example, antenatal care 
distribution is only effective in increasing access to this drug in 
those settings where the majority of women who will deliver 
at home also attend antenatal care. Furthermore, if advanced 
distribution of misoprostol requires a specific gestational age 
among eligible women (eg, in Mozambique, this is 28 weeks 
gestation; in Bangladesh, this is 32 weeks),64,65 only those 
attending antenatal care after the required gestational age 
would receive the drug and be able to use it in home births.
Separate from the interventions themselves is the 
health care system in which these interventions are being 
implemented. The continuum of care is an important con-
sideration because these interventions in isolation will likely 
not be enough to prevent maternal morbidity and mortality. 
These interventions are not a replacement for a weak health 
care infrastructure and limited health care personnel, which 
must not be forgotten in this discussion of PPH prevention 
interventions.
The implementation of effective approaches is also 
dependent on the timely translation of research findings into 
policies and programs, which remains a considerable bar-
rier in accelerating PPH prevention efforts. In general, the 
translation of research into clinical practice is often concep-
tualized as proceeding from awareness through acceptance 
to adoption.66 However, decades may pass before research 
findings are integrated into guidelines and routine clinical 
practice (see Figure 1). There is no agreement or set of rules 
among policy makers regarding the amount of evidence needed 
(ie, number and type of studies) to prompt changes in policies 
and programs. As mentioned before, by 2007, there was only 
one RCT published on the use of misoprostol in home births, 
which prompted Mathai et al to express, after the 2007 release 
of the WHO guidelines, that there was “insufficient evidence 
for the safe use of misoprostol by lay providers in nonfacility 
settings.”67 Nonetheless, based solely on the evidence of its effi-
cacy in clinical settings and encouraged by the potential impact 
that misoprostol could have in the absence of oxytocin, many 
countries had already begun conducting operations research 
to test its safety, feasibility, and acceptability for home births, 
even before consensus was reached and the official guidelines 
were in place.68,69 Eventually, a placebo-controlled RCT with T
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traditional birth attendants was conducted, from 2006 to 2008, 
in Pakistan.45 Similar to the history of misoprostol, but with 
less debate, AMTSL was first described in 1962,11 but the first 
RCT comparing AMTSL with expectant management was 
not done until 1988,12 and the official guidelines and policies 
were not adapted until later,13 after many countries had already 
begun to incorporate this practice. The evidence of the relative 
importance of its components has only become available in the 
last 3 years, prompting the WHO to review its recommendations 
(see Table 1). Finally, the challenges in the use of evidence to 
recommend improvements in the quality of care are further 
complicated by the delays in provider uptake of practices based 
on new knowledge. Even when health providers recognize 
and accept guidelines, they may fail to adopt them,70 and PPH 
prevention efforts are no exception.62
As noted, the translation of research into policy is often a 
long and inconsistent process, and the prioritization of a health 
intervention based solely on costs or cost-effectiveness is an 
equally challenging proposition. However, in resource-poor 
settings, the reduction of maternal mortality in the most cost-
effective way possible should be a priority to policy makers.71 
In a modeling exercise, the prevention of PPH with advanced 
distribution of misoprostol was found to be very cost-effective 
in resource-poor settings, relative to other maternal-health 
interventions included in the WHO Mother-Baby Package, 
only preceded by family planning and safe abortion.72 The cost 
of each intervention recommended by the WHO might differ 
due to the cost of each uterotonic.67 The costs of services also 
depend on the level of health facility and provider involved. 
However, given that PPH is the main cause of maternal death, 
saving lives with any PPH prevention intervention is an 
effective way to reduce overall maternal mortality, which is 
the goal of every developing country, in accordance with the 
United Nations Millennium Development Goal (MDG) 5. An 
economic assessment of the reduction of PPH in developing 
countries estimated that the consistent use of a conventional 
uterotonic in every birth could avert 41 million cases of PPH, 
resulting in an estimated 1.4 million lives saved.73 Specifically 
with regard to misoprostol, an article utilizing modeling tech-
niques determined that misoprostol use for PPH prevention 
is a cost-effective intervention that could reduce maternal 
deaths by approximately 38%.74
Opportunities in PPH prevention
evidence to action
One of the greatest opportunities in PPH prevention is the fact 
that the currently available evidence is sufficient to establish 
policies and programs that will increase access to effective 
interventions in low-resource settings. In order to lever-
age this opportunity, countries must establish a supportive 
national policy, which starts with the adoption of national 
guidelines for PPH prevention that reflect the latest research 
and the most recent WHO recommendations.3,20 Early on, it is 
important to identify local champions who will engage policy 
makers and clinicians.75 With respect to misoprostol, coun-
tries must register it for PPH prevention and ensure its inclu-
sion on the national Essential Medicines List.20 The next step 
for any of the interventions is to secure adequate funding in 
the national budget to ensure the consistent availability of the 
drugs and the training of health care providers.20 With regards 
to misoprostol, correct use by community health workers 
and women could be increased if misoprostol is procured in 
indication-specific packaging, with 600 μg packets for PPH 
prevention,69 and if PPH prevention information is included 
as part of information, education, and communication (IEC) 
mass media campaigns. Another crucial step is the building 
of community awareness and demand for services and drugs, 
which will help to ensure the success of any of the PPH pre-
vention interventions, home- or facility-based. Specifically 
related to the community-based distribution of misoprostol, 
several countries have conducted successful pilot projects, 
and some, including Ghana, Nepal, Niger, and Bangladesh, 
are currently working to scale-up misoprostol access.20,28,76,77 
Country-to-county regional exchanges involving countries 
that have already begun to change and implement national 
PPH prevention policies would provide a great opportunity 
to share experiences and best practices.75
Moving from evidence to action, particularly with regard 
to misoprostol, is an important next step in improving PPH 
prevention that needs to be prioritized in low-resource 
countries.75 Involving community-based and lay providers, 
to the extent the evidence allows, should be an integral part 
of this step.28 Community health workers are being engaged 
more regularly in task-shifting strategies to provide basic 
health services, including the prevention of PPH.63,78,79 In a 
recent integrative review of 18 programs using lay health care 
workers to provide misoprostol via advanced distribution or 
at-delivery distribution, Smith et al found that high coverage 
and use of misoprostol can be achieved via multiple routes 
of distribution.63 In addition, very low rates of incorrect use 
were found.63
New PPH prevention interventions
Other opportunities are on the horizon with regard to 
new drug formulations/drugs and delivery mechanisms. 
Oxytocin is the preferred drug for preventing and  managing 
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PPH.3 However, in its current formulation, oxytocin is not 
heat stable and therefore an impractical intervention in 
many low-resource settings where extreme heat is coupled 
with limited access to refrigeration.51 Yet it is in these low-
resource settings that we see the majority of maternal deaths; 
therefore, research on oxytocin formulations that are heat 
stable is paramount. Two research teams are currently leading 
efforts in this field.80 A team at Monash University, Australia 
is working to develop oxytocin for aerosol delivery,81 and 
this formulation would allow women to inhale oxytocin 
immediately after childbirth, with no refrigeration of the 
product required. A nonprofit pharmaceutical development 
group in the Netherlands is attempting to stabilize oxytocin 
under tropical conditions.82
Another way to potentially increase access to oxyto-
cin is to diversify its route of delivery. Oxytocin in the 
Uniject™ auto-disable injection system (Uniject; BD 
Biosciences, Franklin Lakes, NJ, USA) is comprised of 
a plastic, nonreusable, disposable syringe that is prefilled 
with a single dose of 10 international units (IU) of oxyto-
cin in 1 mL. Given its simple design and safety features, 
Uniject can be used by lay health workers, which is the 
reason oxytocin in Uniject is an important innovation for 
resource-poor settings.83 Oxytocin in Uniject is produced 
by an Argentine pharmaceutical distributor that has regula-
tory approval in eight countries in Latin America. Though 
it is not yet broadly available, access to oxytocin in Uniject 
would be particularly important in countries where human 
resources are limited and where task-shifting to lower 
cadres of health professionals is necessary.84 Field studies 
in several countries have demonstrated the acceptability 
of oxytocin in Uniject among health workers with less 
training, due to its ease of use.85−87 The oxytocin in Uniject 
is not heat stable, but the product packaging provides a 
straightforward time-temperature indicator to allow health 
workers to monitor heat exposure.84 Given the early success 
of oxytocin in Uniject, the WHO has amended its Model 
List of Essential Medicines to include oxytocin in Uniject. 
However, the path to the expanded availability of oxytocin 
in Uniject will require a concurrent increase in demand and 
supply to counter the challenges of low-volume/high-price 
production.84
Another recent innovation in the prevention of PPH is 
carbetocin, a long-acting oxytocin agonist, which mimics 
the action of oxytocin and helps to reduce blood loss.88 Car-
betocin is currently indicated for the prevention of uterine 
atony after delivery by cesarean section in spinal or epidural 
anesthesia in 23 countries, but it is not approved for vaginal 
births. However, it has had proven success in the prevention 
of PPH, due to its longer duration of action and demonstrated 
fewer side effects in several studies.88 Further research is 
necessary to determine the cost effectiveness of carbetocin 
as a uterotonic agent.88 It is also important to assess the 
feasibility and acceptability of carbetocin in the prevention 
of PPH in vaginal deliveries in low-resource settings. For-
tunately, in the 2012 Annual Technical Report of the WHO 
Special Program of Research, Development and Research 
Training in Human Reproduction, plans were announced 
for a multicenter, controlled trial in 2014 that will compare 
a new heat-stable formulation of carbetocin with oxytocin, 
for use in low- and middle-income countries.89
Another intervention that presents an opportunity for 
preventing PPH in home births but that has limited evidence 
of effectiveness is the home-based life-saving skills (HBLSS) 
package. HBLSS is “a community- and competency-based 
program that aims to reduce maternal and neonatal mortality 
by increasing access to basic life-saving measures within the 
home and community and by decreasing delays in reaching 
referral facilities where life threatening problems can be man-
aged.”90 HBLSS is implemented by HBLSS guides who are 
selected by the community and who are then trained using a 
modular design that focuses on the prevention, recognition, 
and initial home management of life-threatening maternal and 
newborn problems and referral to a facility, where possible.91 
These guides then share their HBLSS knowledge and skills 
with women, family caregivers, and homebirth attendants 
(ie, people involved in delivery care and decision making) 
by way of group discussions, demonstrations, and use of 
pictorial learning cards.90,91 When implemented within an 
existing health care infrastructure, the instruction of family 
and community members in techniques such as uterine fun-
dal massage and emergency preparedness has the potential 
to reduce maternal morbidity and mortality due to PPH.23 
The potential effectiveness of this approach in relation to 
PPH relies on early identification of hemorrhage and quick 
initiation of treatment. The findings from an evaluation of a 
field test of HBLSS in Ethiopia were promising.91 Pre- and 
posttraining tests of HBLSS guides’ PPH knowledge demon-
strated a statistically significant increase, and although lower, 
the knowledge remained much higher than the pretraining 
levels at 1 year posttraining.91 In addition, the management of 
PPH (according to postpartum interviews) was significantly 
better among women who delivered with an HBLSS guide 
compared with another unskilled attendant.91 Other similar 
programs implemented in low-resource settings have shown 
success in increasing the coverage of uterotonics and/or 
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reducing PPH by actively engaging women, the commu-
nity, and traditional birth attendants in community-based 
interventions and using locally produced materials to gauge 
blood loss.92−94
Public–private partnership
Public−private partnerships need to be further developed to 
ensure better collaboration in the procurement, distribution, 
and marketing of uterotonics. For example, local pharma-
ceutical manufacturers, distributors, or mobile network 
providers can be partners in creating demand through their 
extensive network of product retailers, that could support the 
dissemination of information about misoprostol.95 In addi-
tion, new mobile technologies are being tested to support 
supply chain management, provide training and diagnostic 
assistance for health workers, and disseminate information 
in hard-to-reach communities. Text messaging is being used 
to collect and transmit a wide range of information, from the 
documentation of stock levels of commodities to the circula-
tion of information to women about where and how to access 
maternal health care.96
Conclusion
As PPH is the main cause of maternal mortality worldwide, 
PPH prevention interventions need to be prioritized as 
an essential way to improve maternal health. There is no 
panacea that can be universally implemented. Each country 
must develop its own context-dependent policies and pro-
grams, incorporating myriad approaches that combine the 
most recent recommendations and reflect the experiences 
of other countries. Though oxytocin is the recommended 
uterotonic, it is not readily available in settings with the 
highest risk for mortality and morbidity from PPH, due to 
its sensitivity to heat and need for provision by a skilled 
provider. Yet increasing access to prophylactic uterotonics, 
regardless of where deliveries occur, should be the primary 
means of reducing the burden of this complication. There 
is still some debate as to whether misoprostol is effective 
in PPH prevention,97 and some have called for additional 
high-quality studies that demonstrate significant reductions 
in PPH.48 But at the present time, based on the evidence 
available, the best way to reduce PPH deaths in low-resource 
settings where women continue to deliver without access 
to a skilled birth attendant is to make misoprostol widely 
available. Therefore, efforts need to be directed at increasing 
misoprostol supplies and supporting correct and consistent 
utilization by providers and by women themselves, in the 
case of home births.
Acknowledgments
The authors would like to thank Tiana Kazemi for her assis-
tance in reviewing the literature.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. World Health Organization (WHO). Reducing the global burden: 
postpartum haemorrhage. Making Pregnancy Safer. 2007;(4):1, 8.
 2. AbouZahr C. Global burden of maternal death and disability. Br Med 
Bull. 2003;67:1–11.
 3. Dept of Reproductive Health and research, World Health Organization 
(WHO). WHO Recommendations for the Prevention and Treatment of 
Postpartum Haemorrhage. Geneva: WHO; 2012.
 4. Prata N, Passano P, Rowen T, Bell S, Walsh J, Potts M. Where there 
are (few) skilled birth attendants. J Health Popul Nutr. 2011;29(2): 
81–91.
 5. Abalos E. Choice of uterotonic agents in the active manage-
ment of the third stage of labour: RHL commentary [webpage on 
the Internet]. Geneva: WHO Reproductive Health Library; 2009 
[updated March 2, 2009]. Available from: http://apps.who.int/rhl/
pregnancy_childbirth/childbirth/3rd_stage/cd000201_abalose_com/
en/. Accessed September 1, 2013.
 6. Prata N, Hamza S, Bell S, Karasek D, Vahidnia F, Holston M. Inability 
to predict postpartum hemorrhage: insights from Egyptian intervention 
data. BMC Pregnancy Childbirth. 2011;11:97.
 7. du Vigneaud V, Ressler CJM, Swan JM, Roberts CW, Katsoyan-
nis PG. The synthesis of oxytocin. J Am Chem Soc. 1954;76(12): 
3115–3121.
 8. du Vigneaud V, Ressler CJM, Swan J, Roberts CW, Katsoyannis PG, 
Godon S. The synthesis of an octapeptide amide with the hormonal 
activity of oxytocin. J Am Chem Soc. 1953;76(19):4879–4880.
 9. du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in 
oxytocin, with a proposal for the structure of oxytocin. J Biol Chem. 
1953;205(2):949–957.
 10. Tuppy H: The amino-acid sequence in oxytocin. Biochim Biophys Acta. 
1953;11:449–450.
 11. Spencer PM. Controlled cord traction in management of the third stage 
of labour. Br Med J. 1962;1(5294):1728–1732.
 12. Prendiville WJ, Harding JE, Elbourne DR, Stirrat GM. The Bristol third 
stage trial: active versus physiological management of third stage of 
labour. BMJ. 1988;297(6659):1295–1300.
 13. International Confederation of Midwives (ICM); International 
 Federation of Gynaecology and Obstetrics (FIGO). Joint Statement: 
Management of the Third Stage of Labour to Prevent Post-partum 
Haemorrhage. New York, NY: FIGO and ICM; 2003.
 14. Prata N, Passano P, Bell S, Rowen T, Potts M. New hope: community-
based misoprostol use to prevent postpartum haemorrhage. Health 
Policy Plan. 2013;28(4):339–346.
 15. Derman RJ, Kodkany BS, Goudar SS, et al. Oral misoprostol 
in preventing postpartum haemorrhage in resource-poor com-
munities: a randomised controlled trial. Lancet. 2006;368(9543): 
1248–1253.
 16. World Health Organization. WHO Recommendations for the Preven-
tion of Postpartum Haemorrhage. Geneva: World Health Organization; 
2007.
 17. Jadesimi A, Okonofua FE. Tackling the unacceptable: Nigeria approves 
misoprostol for postpartum haemorrhage. J Fam Plann Reprod Health 
Care. 2006;32(4):213–214.
 18. World Health Organization. The Selection and Use of Essential 
Medicines (2011). Geneva: World Health Organization; 2011. Available 
from: http://www.who.int/medicines/publications/essentialmeds_
committeereports/en/. Accessed September 2, 2013.
International Journal of Women’s Health 2013:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
750
Prata et al
 19. United Nations. UN Commission on Life-Saving Commodities for 
Women and Children: Commissioners’ Report Sep 2012. New York, 
NY: United Nations; 2012.
 20. Family Care International; PATH; International Federation of 
Gynaecology and Obstetrics (FIGO); Gynuity. Policy Brief. Scaling 
Up Misoprostol for Postpartum Hemorrhage: Moving from Evidence 
to Action. New York, NY: Family Care International; 2012.
 21. Karanja J, Muganyizi P, Rwamushaija E, Hodoglugil N, Holm E; 
Regional Experts’ Summit Group. Confronting maternal mortality due 
to postpartum hemorrhage and unsafe abortion: a call for commitment. 
Afr J Reprod Health. 2013;17(2):18–22.
 22. mchip.net [homepage on the Internet]. Prevention of Postpartum Hemor-
rhage. Maternal and Child Health Integrated Program (MCHIP); 2012. 
Available from: http://www.mchip.net/Postpartum%20Hemorrhage. 
Accessed July 5, 2013.
 23. Lalonde A; International Federation of Gynecology and Obstetrics. 
Prevention and treatment of postpartum hemorrhage in low-resource 
settings. Int J Gynaecol Obstet. 2012;117(2):108–118.
 24. Aflaifel N, Weeks AD. Active management of the third stage of labour. 
BMJ. 2012;345:e4546.
 25. Begley CM. A comparison of ‘active’ and ‘physiological’ management 
of the third stage of labour. Midwifery. 1990;6(1):3–17.
 26. Patted SS, Goudar SS, Naik VA, et al. Side effects of oral misoprostol 
for the prevention of postpartum hemorrhage: results of a community-
based randomised controlled trial in rural India. J Matern Fetal Neonatal 
Med. 2009;22(1):24–28.
 27. Elati A, Weeks A. Misoprostol for the management of postpartum 
haemorrhage. BMJ. 2011;342:d2877.
 28. Ejembi CL, Norick P, Starrs A, Thapa K. New global guidance supports 
community and lay health workers in postpartum hemorrhage preven-
tion. Int J Gynaecol Obstet. 2013;122(3):187–190.
 29. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active versus 
expectant management for women in the third stage of labour. Cochrane 
Database Syst Rev. 2011;(11):CD007412.
 30. Althabe F, Alemán A, Tomasso G, et al. A pilot randomized controlled 
trial of controlled cord traction to reduce postpartum blood loss. Int J 
Gynaecol Obstet. 2009;107(1):4–7.
 31. Deneux-Tharaux C, Sentilhes L, Maillard F, et al. Effect of routine 
controlled cord traction as part of the active management of the third 
stage of labour on postpartum haemorrhage: multicentre randomised 
controlled trial (TRACOR). BMJ. 2013;346:f1541.
 32. Gülmezoglu AM, Lumbiganon P, Landoulsi S, et al. Active management 
of the third stage of labour with and without controlled cord traction: 
a randomised, controlled, non-inferiority trial. Lancet. 2012;379(9827): 
1721–1727.
 33. McDonald SJ, Middleton P, Dowswell T, Morris PS. Effect of timing 
of umbilical cord clamping of term infants on maternal and neonatal 
outcomes [review]. Cochrane Database Syst Rev. 2013;7:CD004074.
 34. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for 
preventing postpartum haemorrhage [review]. Cochrane Database Syst 
Rev. 2013;7:CD006431.
 35. Chantrapitak W, Srijuntuek K, Wattanaluangarun R. The efficacy of lower 
uterine segment compression for prevention of early postpartum hemor-
rhage after vaginal delivery. J Med Assoc Thai. 2011;94(6): 649–656.
 36. Cotter AM, Ness A, Tolosa JE. Prophylactic oxytocin for the third 
stage of labour. [review]. Cochrane Database of Systematic Reviews. 
2001;4:CD001808.
 37. Güngördük K, Asicioglu O, Besimoglu B, et al. Using intraumbilical 
vein injection of oxytocin in routine practice with active management of 
the third stage of labor: a randomized controlled trial. Obstet Gynecol. 
2010;116(3):619–624.
 38. Puri M, Taneja P, Gami N, Rehan HS. Effects of different doses of 
intraumbilical oxytocin on the third stage of labor. Int J Gynaecol 
Obstet. 2012;118(3):210–212.
 39. Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Prophylactic 
use of ergot alkaloids in the third stage of labour [review]. Cochrane 
Database Syst Rev. 2007;2:CD005456.
 40. Oladapo OT. Misoprostol for preventing and treating postpartum hemor-
rhage in the community: a closer look at the evidence. Int J Gynaecol 
Obstet. 2012;119(2):105–110.
 41. Olefile KM, Khondowe O, M’rithaa D. Misoprostol for prevention and 
treatment of postpartum haemorrhage: a systematic review. Curationis. 
2013;36(1):E1–E10.
 42. Tuncalp O, Hofmeyr GJ, Gülmezoglu AM. Prostaglandins for preventing 
postpartum haemorrhage [review]. Cochrane Database Syst Rev. 
2012;8:CD000494.
 43. Høj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of 
sublingual misoprostol on severe postpartum haemorrhage in a primary 
health centre in Guinea-Bissau: randomised double blind clinical trial. 
BMJ. 2005;331(7519):723.
 44. Surbek DV, Fehr PM, Hösli I, Holzgreve W. Oral misoprostol for third 
stage of labor: a randomized placebo-controlled trial. Obstet Gynecol. 
1999;94(2):255–258.
 45. Mobeen N, Durocher J, Zuberi N, et al. Administration of misoprostol by 
trained traditional birth attendants to prevent postpartum haemorrhage 
in homebirths in Pakistan: a randomised placebo-controlled trial. BJOG. 
2011;118(3):353–361.
 46. Tsu VD, Mai TT, Nguyen YH, Luu HT. Reducing postpartum hemor-
rhage in Vietnam: assessing the effectiveness of active management 
of third-stage labor. J Obstet Gynaecol Res. 2006;32(5):489–496.
 47. Sheldon WR, Durocher J, Winikoff B, Blum J, Trussell J. How effective 
are the components of active management of the third stage of labor? 
BMC Pregnancy Childbirth. 2013;13:46.
 48. Hundley VA, Avan BI, Sullivan CJ, Graham WJ. Should oral 
misoprostol be used to prevent postpartum haemorrhage in home-birth 
settings in low-resource countries? A systematic review of the evidence. 
BJOG. 2013;120(3):277–285; discussion 286–277.
 49. Mir AM, Wajid A, Gull S. Helping rural women in Pakistan to prevent 
postpartum hemorrhage: a quasi experimental study. BMC Pregnancy 
Childbirth. 2012;12:120.
 50. Hashima EN, Nahar S, Al Mamun M, Afsana K, Byass P. Oral 
misoprostol for preventing postpartum haemorrhage in home births in 
rural Bangladesh: how effective is it? Glob Health Action. 2011;4.
 51. World Health Organization (WHO). Stability of Oral Oxytocics 
in  Tropical Climates − Results of Simulation Studies on Oral 
Ergomentrine, Oral Methlyergometrine, Buccal Oxytocin and Buccal 
Desamino-Oxytocin. Geneva: WHO; 1994.
 52. United Nations Children’s Fund (UNICEF). The State of the World’s Children 
2009: Maternal and Newborn Health. New York, NY: UNICEF; 2008.
 53. MEASURE DHS STATcompiler. Demographic and health survey, 
USAID: STAT compiler. ICF International 2012. www.statcompiler.
com. Accessed July 6, 2013.
 54. World Health Organization (WHO). Working Together for Health. The 
World Health Report 2006. Geneva: WHO; 2006.
 55. Department of Reproductive Health and Research, World Health 
Organization (WHO). Proportion of Births Attended by a Skilled Health 
Worker: 2008 Updates. Geneva: WHO; 2008.
 56. Lawn JE, Kinney M, Lee AC, et al. Reducing intrapartum-related deaths 
and disability: can the health system deliver? Int J Gynaecol Obstet. 
2009;107 Suppl 1:S123–S40, 140.
 57. Hogerzeil HV, Walker GJ. Instability of (methyl)ergometrine in tropical 
climates: an overview. Eur J Obstet Gynecol Reprod Biol. 1996;69(1): 
25–29.
 58. Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S. 
Uterotonic drug quality: an assessment of the potency of injectable 
uterotonic drugs purchased by simulated clients in three districts in 
Ghana. BMJ Open. 2012;2(3).
 59. Hofmeyr GJ, Walraven G, Gülmezoglu AM, Maholwana B, 
Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: 
a systematic review. BJOG. 2005;112(5):547–553.
 60. Prevention of Postpartum Hemorrhage Initiative (POPPHI). 
 Facility-Based Management of the Third Stage of Labor and  Community 
Perceptions and Actions on Postpartum Hemorrhage:  Findings 
from a National Survey in Ethiopia. Washington, DC: POPPHI; 2006.
International Journal of Women’s Health 2013:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
751
Prevention of postpartum hemorrhage
 61. Prevention of Postpartum Hemorrhage Initiative (POPPHI). 
 Facility-Based Management of the Third Stage of Labor and Community 
Perceptions and Actions on Postpartum Hemorrhage: Findings from a 
National Survey in Tanzania. Washington, DC: POPPHI; 2006.
 62. Festin MR, Lumbiganon P, Tolosa JE, et al. International survey on 
variations in practice of the management of the third stage of labour. 
Bull World Health Organ. 2003;81(4):286–291.
 63. Smith JM, Gubin R, Holston MM, Fullerton J, Prata N. Misoprostol 
for postpartum hemorrhage prevention at home birth: an integrative 
review of global implementation experience to date. BMC Pregnancy 
Childbirth. 2013;13:44.
 64. Venture Strategies Innovations (VSI). Prevention of Postpartum 
 Hemorrhage in Home Births: Misoprostol Distribution during Antenatal 
Care Visits in Tanzania – Final Report in Brief. Irvine, CA: VSI; 2011. 
Available from: http://www.vsinnovations.org/assets/files/Program 
Briefs/Ifakara Tanzania Brief 2011F (compressed).pdf. Accessed 
July 15, 2013.
 65. Venture Strategies Innovations (VSI). Community-Based Prevention 
of Postpartum Hemorrhage with Misoprostol in Mozambique. Final 
Report in Brief. Irvine, CA: VSI; 2011. Available from: http://www.
vsinnovations.org/assets/files/Program Briefs/VSI_AMOG_Bixby_
PSI Moz PPH Brief 2011 06F ENG Compressed.pdf. Accessed 
July 15, 2013.
 66. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. 
A systematic review of theoretic concepts, practical experience and 
research evidence in the adoption of clinical practice guidelines. CMAJ. 
1997;157(4):408–416.
 67. Mathai M, Gulmezoglu AM, Hill S. Saving womens lives: evidence-
based recommendations for the prevention of postpartum haemorrhage. 
Bull World Health Organ. 2007;85(4):322–323.
 68. Rajbhandari S, Hodgins S, Sanghvi H, McPherson R, Pradhan YV, 
Baqui AH; Misoprostol Study. Expanding uterotonic protection follow-
ing childbirth through community-based distribution of misoprostol: 
operations research study in Nepal. Int J Gynaecol Obstet. 2010;108(3): 
282–288.
 69. Sanghvi H, Ansari N, Prata NJ, Gibson H, Ehsan AT, Smith JM. 
Prevention of postpartum hemorrhage at home birth in Afghanistan. 
Int J Gynaecol Obstet. 2010;108(3):276–281.
 70. Green LA, Seifert CM. Translation of research into practice: why we 
can’t “just do it”. J Am Board Fam Pract. 2005;18(6):541–545.
 71. Jowett M. Safe Motherhood interventions in low-income countries: 
an economic justification and evidence of cost effectiveness. Health 
Policy. 2000;53(3):201–228.
 72. Prata N, Sreenivas A, Greig F, Walsh J, Potts M. Setting priorities 
for safe motherhood interventions in resource-scarce settings. Health 
Policy. 2010;94(1):1–13.
 73. Seligman B, Liu X. Economic Assessment of Interventions for Reducing 
Postpartum Hemorrhage in Developing Countries. Bethesda, MD: Abt 
Associates Inc; 2006.
 74. Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal 
iron supplementation as maternal mortality interventions in home births 
in rural India. Int J Gynaecol Obstet. 2009;104(3):189–193.
 75. Starrs A, Winikoff B. Misoprostol for postpartum hemorrhage: 
moving from evidence to practice. Int J Gynaecol Obstet. 2012; 
116(1):1–3.
 76. Prevention of Postpartum Hemorrhage Initiative (POPPHI). 
Report of a POPPHI Visit to the Quality Assurance Project Sites in 
Niger, West Africa, April 18–25, 2008. Seattle, WA: Program for 
Appropriate Technology in Health (PATH); 2008.
 77. Family Care International; Gynuity. Misoprostol for Postpartum 
Hemorrhage: Reaching Women Wherever They Give Birth. Stories of 
Success in Bangladesh, Nepal, and Zambia. New York, NY: Family 
Care International; 2012.
 78. World Health Organization (WHO), PEPFAR, UNAIDS. Task Shifting: 
Rational Redistribution of Tasks Among Health  Workforce Teams – Global 
Recommendations and Guidelines. Geneva: WHO; 2008.
 79. World Health Organization (WHO). Optimizing Health Worker Roles 
to Improve Access to Key Maternal and Newborn Health Interventions 
Through Task Shifting. Geneva: WHO; 2012.
 80. Program for Appropriate Technology in Health (PATH). Heat-Stable 
Oxytocin. Technology Opportunity Assessment. Seattle, WA: PATH; 
2012.
 81. monash.edu.au [homepage on the Internet]. New drug delivery to save 
the lives of women [press release]. Monash University; 2012. Available 
from: http://www.monash.edu.au/news/show/new-drug-delivery-to-
save-the-lives-of-women. Accessed July 8, 2013.
 82. tipharma.com [homepage on the Internet]. Hot medicines: stability 
of protein-based medicines. TI Pharma; 2012. Available from: http://
www.tipharma.com/pharmaceutical-research-projects/production-
technologies/oxytocin-hot-medicines.html. Accessed July 8, 2013.
 83. Program for Appropriate Technology in Health (PATH); USAID. 
 Introducing Oxytocin in the Uniject Device: An Overview for 
Decision-Makers. Seattle, WA: PATH; 2008.
 84. Program for Appropriate Technology in Health (PATH). Oxytocin in the 
Uniject Prefilled Injection System. Technology Opportunity Assess-
ment. Seattle, WA: PATH; 2012.
 85. Tsu VD, Sutanto A, Vaidya K, Coffey P, Widjaya A. Oxytocin in prefilled 
Uniject injection devices for managing third-stage labor in Indonesia. 
Int J Gynecol Obstet. 2003;83(1):103–111.
 86. Althabe F, Mazzoni A, Cafferata ML, et al. Oxytocin in Uniject Study 
Group. Using Uniject to increase the use of prophylactic oxytocin for 
management of the third stage of labor in Latin America. Int J Gynaecol 
Obstet. 2011;114(2):184–189.
 87. Low LK, Bailey JM, Sacks E, Robles C, Medina L. Reduced post-
partum hemorrhage after implementation of active management of 
the third stage of labor in rural Honduras. Int J Gynaecol Obstet. 
2012;119(3):217–220.
 88. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum hae-
morrhage [review]. Cochrane Database Syst Rev. 2012;4:CD005457.
 89. Department of Reproductive Health and Research, World Health 
Organization (WHO). Annual Technical Report 2012. Geneva: WHO; 
2013.
 90. Sibley L, Buffington ST, Beck D, Armbruster D. Home based life saving 
skills: promoting safe motherhood through innovative community-based 
interventions. J Midwifery Womens Health. 2001;46(4):258–266.
 91. Sibley L, Buffington ST, Haileyesus D. The American College of 
Nurse-Midwives’ home-based lifesaving skills program: a review of the 
Ethiopia field test. J Midwifery Womens Health. 2004;49(4):320–328.
 92. Prata N, Ejembi C, Fraser A, Shittu O, Minkler M. Community 
mobilization to reduce postpartum hemorrhage in home births in 
northern Nigeria. Soc Sci Med. 2012;74(8):1288–1296.
 93. Prata N, Mbaruku G, Campbell M, Potts M, Vahidnia F. Controlling 
postpartum hemorrhage after home births in Tanzania. Int J Gynaecol 
Obstet. 2005;90:51–55.
 94. Prata N, Quaiyum MA, Passano P, et al. Training traditional birth 
attendants to use misoprostol and an absorbent delivery mat in home 
births. Soc Sci Med. 2012;75(11):2021–2027.
 95. The Zambia Forum for Health Research (ZAMFOHR). Preventing 
Community-Based Postpartum Haemorrhage in Zambia: Policy Dia-
logue Report. Lusaka: ZAMFOHR; 2011.
 96. Blake S, Cody A, Kaur A, et al; Maternal Health Task Force; Global Health 
Vision. UN Commission on Life Saving Commodities for Women and 
Children: Country Case Studies. New York, NY: United Nations; 2012.
 97. Chu CS, Brhlikova P, Pollock AM. Rethinking WHO guidance: review 
of evidence for misoprostol use in the prevention of postpartum 
 haemorrhage. J R Soc Med. 2012;105(8):336–347.
International Journal of Women’s Health
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-womens-health-journal
The International Journal of Women’s Health is an international, peer-
reviewed open-access journal publishing original research, reports, 
editorials, reviews and commentaries on all aspects of women’s 
healthcare including gynecology, obstetrics, and breast cancer. The 
manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
International Journal of Women’s Health 2013:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
752
Prata et al
